Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients

Oncology

Volumn 73, Issue 3-4, 2008, Pages 210-214

  Kurtz, J E ^a   Rousseau, F ^c   Meyer, N ^a   Delozier, T ^d   Serin, D ^e   Nabet, M ^f   Djafari, L ^g   Dufour, P ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CENTRE PAUL STRAUSS   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e INSTITUT SAINTE CATHERINE   (France)

^f Clinique Claude Bernard   (France)

^g Schering Plough   (France)

Author keywords

Breast cancer; Cyclophosphamide; Older; Pegylated liposomal doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 43049109178     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127411     Document Type: Article

References (14)

1. Ranson MR, Cheeseman S, White S, Margison: Caelyx in the treatment of advanced breast cancer. Clin Rev Oncol 2001;37:115-120.
2. Owainati A, Zalupski M, Shields A, Hussain M, Philip PA: Phase I study of liposomal doxorubicin and cyclophosphamide in tumors (abstract 954). Proc Am Soc Clin Oncol 1998;17:249a.
3. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC: Pegylated lipososomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 2005;6:150-157.
4. Kurtz JE, Dufour P: Strategies for improving quality of life in elderly patients with metastatic breast cancer. Drugs Aging 2002;19:605-622.
5. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershmann DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005;23:8597-8605.
6. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem N, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-1047.
7. Chan S, Davidson N, Juozaityte E, Erdkamp F, Plusanska A, Azarnia N, Lee LW: Phase III trial of liposomal doxorubibin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527:1534.
8. O'Brien ME, Wigler N, Inbar M, , Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler CL: Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
9. Batist G, Ramakrishnan B, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial. J Clin Oncol 2001;19:1444-1454.
10. Valero V, Buzdar AU, Theriault RL, Azarnia, N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hotobagyi GN: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide and fluorouracil as first line therapy in patients with metastatic bresat cancer. J Clin Oncol 1999;17:1425-1434.
11. Del Mastro, Perrone F, Repetto L, Zagonel V, Fratino L, Marenco D, Venturini M, Maggi E, Bighin C, Catzeddu T, Venturino A, Rosso R: Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol 2005;16:253-258.
12. O'Shaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
13. Bajetta E, Procopio G, Celio, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2161.
14. Kurtz JE, Deplanque G, Borel C, Mathelin C, Prevost G, Poulin G, Barats JC, Bergerat JP, Chapelle-Marcillac I, Bardonnet M, Dufour P: Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer. Ann Oncol 2000;11:229-230.